Composition having effects of preventing or ameliorating conditions or diseases caused by brain hypofunction
The object of the present invention is to provide a composition that has preventive or ameliorative action on symptoms or diseases caused by decreased brain function. This composition contains, as its active ingredient, arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid and, particularly, an alcohol ester of arachidonic acid or a triglyceride, phospholipid or glycolipid in which all or a portion of the constituent fatty acids are arachidonic acid.
1. A method of treating or ameliorating decreased learning ability, decreased cognitive ability, or decreased memory, each of which is caused by decreased brain function accompanying aging in a subject, the method comprising administering to said subject a composition comprising arachidonic acid and/or a compound having arachidonic acid as a constituent fatty acid in a therapeutically effective amount to treat or ameliorate said decreased learning ability, decreased cognitive ability, or decreased memory accompanying aging,
wherein the subject is human, and wherein the therapeutically effective amount for a human adult represents a daily arachidonic acid intake of 0.05-5 g.
2. The method of treating or ameliorating of claim 1 , wherein the compound having arachidonic acid as a constituent fatty acid is an alcohol ester of arachidonic acid or a triglyceride, phospholipid or glycolipid in which all or a portion of the constituent fatty acids are arachidonic acid.
3. The method of treating or ameliorating of claim 2 , wherein the triglyceride in which all or a portion of the constituent fatty acids are arachidonic acid is a triglyceride in which medium-chain fatty acids are bound to 1,3-position and arachidonic acid is bound to 2-position.
4. The method of treating or ameliorating of claim 3 , wherein the medium-chain fatty acids are selected from fatty acids having 6 to 12 carbon atoms.
5. The method of treating or ameliorating of claim 4 , wherein the medium-chain fatty acids are selected from fatty acids having 8 carbon atoms.
6. The method of treating or ameliorating of claim 1 , wherein said compound comprises triglycerides in which all or a portion of the constituent fatty acids are arachidonic acid.
7. The method of treating or ameliorating of claim 6 , wherein the proportion of arachidonic acid in the triglycerides in which all or a portion of the constituent fatty acids are arachidonic acid is 10% by weight or more relative to all of the fatty acids that compose the triglycerides.
8. The method of treating or ameliorating of claim 6 , wherein the triglycerides in which all or a portion of the constituent fatty acids are arachidonic acid are extracted from a microorganism belonging to the genus Mortierella.
9. The method of treating or ameliorating of claim 6 , wherein the triglycerides in which all or a portion of the constituent fatty acids are arachidonic acid are triglycerides that are substantially free of eicosapentaenoic acid.
10. The method of treating or ameliorating of claim 1 , wherein said compound comprises triglycerides containing 5 mol % or more of triglycerides in which medium-chain fatty acids are bound to 1,3-position and arachidonic acid is bound to 2-position.
11. The method of treating or ameliorating of claim 10 , wherein the medium-chain fatty acids are selected from fatty acids having 6 to 12 carbon atoms.
12. The method of treating or ameliorating of claim 10 , wherein the medium-chain fatty acids are selected from fatty acids having 8 carbon atoms.
13. The method of treating or ameliorating of claim 1 , wherein decreased memory or decreased learning ability is treated or ameliorated.
14. The method of treating or ameliorating of claim 1 , wherein decreased cognitive ability is treated or ameliorated.
15. The method of treating or ameliorating of claim 1 , wherein the composition is a food composition or a pharmaceutical composition.
16. The method of treating or ameliorating of claim 1 , wherein said composition additionally comprises docosahexaenoic acid and/or a compound having docosahexaenoic acid as a constituent fatty acid.
17. The method of treating or ameliorating of claim 16 , wherein the compound having docosahexaenoic acid as a constituent fatty acid is an alcohol ester of docosahexaenoic acid or a triglyceride, phospholipid or glycolipid in which all or a portion or the constituent fatty acids are docosahexaenoic acid.
18. The method of treating or ameliorating of claim 16 , wherein the ratio (weight) of arachidonic acid to docosahexaenoic acid in the combination of arachidonic acid and docosahexaenoic acid is within the range of 0.1 to 15.
19. The method of treating or ameliorating of claim 1 , wherein either the composition comprises no eicosapentaenoic acid, or the composition comprises eicosapentaenoic acid at the amount not exceeding one-fifth of the amount of arachidonic acid in the composition.
20. The method of treating or ameliorating of claim 1 , wherein the therapeutically effective amount for a human adult represents a daily arachidonic acid intake of 0.1-2 g.